Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record.

Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan

Open access
KOIKE, TAKAO, HARIGAI, MASAYOSHI, INOKUMA, SHIGEKO, INOUE, KAZUHIKO, ISHIGURO, NAOKI, RYU, JUNNOSUKE, TAKEUCHI, TSUTOMU, TANAKA, YOSHIYA, YAMANAKA, HISASHI, FUJII, KOICHI, FREUNDLICH, BRUCE, SUZUKAWA, MICHIO · 2009 · The Journal of Rheumatology

Abstract

Objective.: Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel®) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN. Methods.: Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients’ background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28). Results.: Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6%); 60% of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3%) and rash (n = 228, 3.2%). Serious AE occurred in 403 patients (5.7%); most frequent were pneumonia (n = 59, 0.8%) and interstitial lung disease (n = 42, 0.6%). Pneumonia was the most common specifically important ADR (n = 102, 1.4%). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1% at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9%. Conclusion.: This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3899/jrheum.080791

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 179

Metadata

Authors
KOIKE, T., HARIGAI, M., INOKUMA, S., INOUE, K., ISHIGURO, N., RYU, J., TAKEUCHI, T., TANAKA, Y., YAMANAKA, H., FUJII, K., FREUNDLICH, B., & SUZUKAWA, M.
Venue
The Journal of Rheumatology
Published
2009-03-30
Volume
36
Issue
5
Pages
898-906
ISSN
  • 0315-162X (ISSN-L)
  • 1499-2752
OpenAlex
W2088723552
Cited by
179
References
0
FWCI
15.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. https://app.cochat.ai/papers/10.3899/jrheum.080791
The paper
KOIKE, T., HARIGAI, M., INOKUMA, S., INOUE, K., ISHIGURO, N., RYU, J., TAKEUCHI, T., TANAKA, Y., YAMANAKA, H., FUJII, K., FREUNDLICH, B., & SUZUKAWA, M. (2009). Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.080791

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.